HRP20251001T1 - Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije - Google Patents

Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije

Info

Publication number
HRP20251001T1
HRP20251001T1 HRP20251001TT HRP20251001T HRP20251001T1 HR P20251001 T1 HRP20251001 T1 HR P20251001T1 HR P20251001T T HRP20251001T T HR P20251001TT HR P20251001 T HRP20251001 T HR P20251001T HR P20251001 T1 HRP20251001 T1 HR P20251001T1
Authority
HR
Croatia
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
HRP20251001TT
Other languages
English (en)
Croatian (hr)
Inventor
Souvik Bhattacharya
Bruno BIETH
Maciej CABANSKI
Bruno CENNI
Stefan De Buck
Martin Kaul
Arvind Kinhikar
Andrijana RADIVOJEVIC
Thomas Severin
Julian STORIM
Alessandra VITALITI GARAMI
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20251001T1 publication Critical patent/HRP20251001T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20251001TT 2019-05-23 2020-05-20 Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije HRP20251001T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
EP20729204.6A EP3972604B1 (en) 2019-05-23 2020-05-20 A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Publications (1)

Publication Number Publication Date
HRP20251001T1 true HRP20251001T1 (hr) 2025-10-24

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251001TT HRP20251001T1 (hr) 2019-05-23 2020-05-20 Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije

Country Status (22)

Country Link
US (2) US12419889B2 (cg-RX-API-DMAC7.html)
EP (2) EP4599894A3 (cg-RX-API-DMAC7.html)
JP (2) JP7568651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012281A (cg-RX-API-DMAC7.html)
CN (1) CN113795255A (cg-RX-API-DMAC7.html)
AU (2) AU2020280272B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138081A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003032A1 (cg-RX-API-DMAC7.html)
DK (1) DK3972604T3 (cg-RX-API-DMAC7.html)
ES (1) ES3039974T3 (cg-RX-API-DMAC7.html)
FI (1) FI3972604T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251001T1 (cg-RX-API-DMAC7.html)
IL (1) IL286983B2 (cg-RX-API-DMAC7.html)
LT (1) LT3972604T (cg-RX-API-DMAC7.html)
MX (2) MX2021013942A (cg-RX-API-DMAC7.html)
PL (1) PL3972604T3 (cg-RX-API-DMAC7.html)
PT (1) PT3972604T (cg-RX-API-DMAC7.html)
RS (1) RS67141B1 (cg-RX-API-DMAC7.html)
SI (1) SI3972604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI868139B (cg-RX-API-DMAC7.html)
WO (1) WO2020234782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa

Also Published As

Publication number Publication date
AU2025252618A1 (en) 2025-11-06
TW202537625A (zh) 2025-10-01
IL286983B1 (en) 2025-09-01
LT3972604T (lt) 2025-09-10
TWI868139B (zh) 2025-01-01
CN113795255A (zh) 2021-12-14
BR112021022602A2 (pt) 2022-01-04
DK3972604T3 (da) 2025-09-15
PL3972604T3 (pl) 2025-09-22
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
IL286983A (en) 2021-12-01
TW202110450A (zh) 2021-03-16
AU2020280272A1 (en) 2021-11-18
ES3039974T3 (en) 2025-10-28
SI3972604T1 (sl) 2025-09-30
JP7568651B2 (ja) 2024-10-16
EP3972604A1 (en) 2022-03-30
CL2021003032A1 (es) 2022-09-09
RS67141B1 (sr) 2025-09-30
US20220184074A1 (en) 2022-06-16
AU2020280272B2 (en) 2025-07-24
FI3972604T3 (fi) 2025-09-01
EP4599894A2 (en) 2025-08-13
KR20220012281A (ko) 2022-02-03
CA3138081A1 (en) 2020-11-26
EP4599894A3 (en) 2025-11-12
JP2024178168A (ja) 2024-12-24
US12419889B2 (en) 2025-09-23
WO2020234782A1 (en) 2020-11-26
EP3972604B1 (en) 2025-06-04
PT3972604T (pt) 2025-08-26
MX2021013942A (es) 2022-01-04
MX2024014626A (es) 2025-01-09
US20250375446A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
FI3972604T3 (fi) Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
FI4088720T3 (fi) Rimegepantti cgrp-liittyviin häiriöihin
FI3519049T3 (fi) Turvallinen ja tehokas menetelmä psoriaasin hoitamiseen il23- spesifisellä vasta-aineella
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
EP4218819A3 (en) Combination therapy based on pd-1 signal inhibitors
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
ME02946B (me) Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
HRP20241584T1 (hr) Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
HRP20250972T1 (hr) Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
FI3634463T3 (fi) Parannettu protokolla lupusnefriitin hoitoon
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
RU2010121919A (ru) Диспиро 1, 2, 4-триоксоланы как противомалярийные средства
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta